

Giulia Marvaso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4952208/publications.pdf>

Version: 2024-02-01

176
papers

1,682
citations

394421

19
h-index

361022

35
g-index

183
all docs

183
docs citations

183
times ranked

2601
citing authors

#	ARTICLE	IF	CITATIONS
1	Modern radiotherapy for head and neck cancer. <i>Seminars in Oncology</i> , 2019, 46, 233-245.	2.2	147
2	Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. <i>European Urology</i> , 2019, 76, 732-739.	1.9	99
3	Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. <i>Cancer Biology and Therapy</i> , 2013, 14, 469-475.	3.4	82
4	Recent advances in radiation oncology. <i>Ecancermedicalsecience</i> , 2017, 11, 785.	1.1	79
5	Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e623-e632.	1.9	71
6	Machine Learning-Based Models for Prediction of Toxicity Outcomes in Radiotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 790.	2.8	59
7	Effects of MRI image normalization techniques in prostate cancer radiomics. <i>Physica Medica</i> , 2020, 71, 7-13.	0.7	52
8	Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: Systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 129, 91-101.	4.4	51
9	Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT). <i>British Journal of Radiology</i> , 2019, 92, 20180494.	2.2	50
10	Voxel-based analysis unveils regional dose differences associated with radiation-induced morbidity in head and neck cancer patients. <i>Scientific Reports</i> , 2017, 7, 7220.	3.3	49
11	Radiation therapy during the coronavirus disease 2019 (covid-19) pandemic in Italy: a view of the nation's young oncologists. <i>ESMO Open</i> , 2020, 5, e000779.	4.5	46
12	COVID-19 outbreak and cancer radiotherapy disruption in Italy: Survey endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). <i>Radiotherapy and Oncology</i> , 2020, 149, 89-93.	0.6	43
13	Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro. <i>Cancer Biology and Therapy</i> , 2014, 15, 797-805.	3.4	40
14	MRI-based radiomics signature for localized prostate cancer: a new clinical tool for cancer aggressiveness prediction? Sub-study of prospective phase II trial on ultra-hypofractionated radiotherapy (AIRO IG-13218). <i>European Radiology</i> , 2021, 31, 716-728.	4.5	31
15	Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. <i>Cancer Treatment Reviews</i> , 2021, 98, 102206.	7.7	30
16	COVID-19 Outbreak and Cancer Radiotherapy Disruption in Lombardy, Northern Italy. <i>Clinical Oncology</i> , 2020, 32, e160-e161.	1.4	27
17	Stereotactic radiotherapy for prostate bed recurrence after prostatectomy, a multicentric series. <i>BJU International</i> , 2020, 125, 417-425.	2.5	24
18	Long-Term Results and Reconstruction Failure in Patients Receiving Postmastectomy Radiation Therapy with a Temporary Expander or Permanent Implant in Place. <i>Plastic and Reconstructive Surgery</i> , 2020, 145, 317-327.	1.4	22

#	ARTICLE	IF	CITATIONS
19	Head and neck cancer radiotherapy amid COVID 19 pandemic: Report from Milan, Italy. <i>Head and Neck</i> , 2020, 42, 1482-1490.	2.0	21
20	A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings. <i>BJU International</i> , 2020, 126, 104-113.	2.5	21
21	Role of EGFR as prognostic factor in head and neck cancer patients treated with surgery and postoperative radiotherapy: proposal of a new approach behind the EGFR overexpression. <i>Medical Oncology</i> , 2017, 34, 107.	2.5	20
22	Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases. <i>Medical Oncology</i> , 2018, 35, 75.	2.5	19
23	Machine Learning for Head and Neck Cancer: A Safe Bet? A Clinically Oriented Systematic Review for the Radiation Oncologist. <i>Frontiers in Oncology</i> , 2021, 11, 772663.	2.8	19
24	Multimodal image registration for the identification of dominant intraprostatic lesion in high-precision radiotherapy treatments. <i>British Journal of Radiology</i> , 2017, 90, 20170021.	2.2	18
25	Whole-body magnetic resonance imaging: technique, guidelines and key applications. <i>Ecancelmedscience</i> , 2021, 15, 1164.	1.1	18
26	Late toxicity of image-guided hypofractionated radiotherapy for prostate: non-randomized comparison with conventional fractionation. <i>Radiologia Medica</i> , 2019, 124, 65-78.	7.7	17
27	Stereotactic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases. <i>Lung Cancer</i> , 2020, 142, 70-79.	2.0	17
28	Multi atlas based segmentation: should we prefer the best atlas group over the group of best atlases?. <i>Physics in Medicine and Biology</i> , 2018, 63, 12NT01.	3.0	16
29	Carotid blowout syndrome after reirradiation for head and neck malignancies: a comprehensive systematic review for a pragmatic multidisciplinary approach. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 155, 103088.	4.4	16
30	IMRT versus 2D/3D conformal RT in oropharyngeal cancer: A review of the literature and meta-analysis. <i>Oral Diseases</i> , 2021, 27, 1644-1653.	3.0	16
31	Rationale and Protocol of AIRC IG-13218, Short-Term Radiotherapy for Early Prostate Cancer with Concomitant Boost to the Dominant Lesion. <i>Tumori</i> , 2016, 102, 536-540.	1.1	15
32	Prognostic significance of neutrophil-to-lymphocyte ratio in HPV status era for oropharyngeal cancer. <i>Oral Diseases</i> , 2020, 26, 1384-1392.	3.0	15
33	Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?. <i>Clinical and Translational Oncology</i> , 2021, 23, 1717-1726.	2.4	15
34	The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of) <i>TJ ETQq0 0 0 rgBT /Overlock 10 Tf 50 142 Td</i> 2021, 38, 527-537.	3.3	14
35	Prognostic value of the PIK3CA, AKT, and PTEN mutations in oral squamous cell carcinoma: literature review. <i>Archives of Medical Science</i> , 2021, 17, 207-217.	0.9	13
36	Phase II Multi-institutional Clinical Trial on a New Mixed Beam RT Scheme of IMRT on Pelvis Combined with a Carbon Ion Boost for High-risk Prostate Cancer Patients. <i>Tumori</i> , 2017, 103, 314-318.	1.1	12

#	ARTICLE	IF	CITATIONS
37	STRA-MI-VT (STereotactic RadioAblation by Multimodal Imaging for Ventricular Tachycardia): rationale and design of an Italian experimental prospective study. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020, 61, 583-593.	1.3	12
38	Interim 18FDG PET/CT during radiochemotherapy in the management of pelvic malignancies: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 28-42.	4.4	11
39	Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-analysis of Prospective Studies. <i>European Urology Open Science</i> , 2021, 27, 19-28.	0.4	11
40	Stereotactic or conventional radiotherapy for macroscopic prostate bed recurrence: a propensity score analysis. <i>Radiologia Medica</i> , 2022, 127, 449-457.	7.7	11
41	Nutritional Intervention for Nonsurgical Head and Neck Cancer Patients Treated with Radiation Therapy: Results from a Prospective Stepped-Wedge Clinical Protocol. <i>Nutrition and Cancer</i> , 2018, 70, 1051-1059.	2.0	10
42	Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Reviews in Oncology/Hematology, 2019, 134, 104-119.	4.4	10
43	Recurrent oligometastatic transitional cell bladder carcinoma: is there room for radiotherapy?. <i>Neoplasma</i> , 2019, 66, 160-165.	1.6	10
44	COVID-19 manifestation in the oral cavity – a narrative literature review. <i>Acta Otorhinolaryngologica Italica</i> , 2021, 41, 395-400.	1.5	10
45	Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218. <i>British Journal of Radiology</i> , 2018, 91, 20160725.	2.2	9
46	Radioablation +/âˆ¬ hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159). <i>BMC Cancer</i> , 2019, 19, 903.	2.6	9
47	Ductal carcinoma in situ and intraoperative partial breast irradiation: Who are the best candidates? Long-term outcome of a single institution series. <i>Radiotherapy and Oncology</i> , 2019, 133, 68-76.	0.6	9
48	PROLAPSE: survey about local prostate cancer relapse salvage treatment with external beam re-irradiation: results of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2311-2317.	2.5	9
49	MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naÃ“ve patients: follow-up of a PRECISION trial-like retrospective cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 406-413.	3.9	9
50	Methods of Topical Administration of Drugs and Biological Active Substances for Dental Implants – A Narrative Review. <i>Antibiotics</i> , 2021, 10, 919.	3.7	9
51	Impact of a dedicated radiologist as a member of the head and neck tumour board: a single-institution experience. <i>Acta Otorhinolaryngologica Italica</i> , 2020, 40, 26-32.	1.5	9
52	Repeat stereotactic radiosurgery in the management of brain metastases from NSCLC: A case report and review of the literature. <i>Oncology Letters</i> , 2013, 6, 897-900.	1.8	8
53	–Give me five–ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach. <i>Medical Oncology</i> , 2018, 35, 96.	2.5	8
54	Any Role of PIK3CA and PTEN Biomarkers in the Prognosis in Oral Squamous Cell Carcinoma?. <i>Life</i> , 2020, 10, 325.	2.4	8

#	ARTICLE	IF	CITATIONS
55	Effects of Sex and Age on Fat Fraction, Diffusion-Weighted Image Signal Intensity and Apparent Diffusion Coefficient in the Bone Marrow of Asymptomatic Individuals: A Cross-Sectional Whole-Body MRI Study. <i>Diagnostics</i> , 2021, 11, 913.	2.6	8
56	The Current Status of Novel PET Radio-Pharmaceuticals in Radiotherapy Treatment Planning of Glioma. <i>Current Pharmaceutical Biotechnology</i> , 2014, 14, 1099-1104.	1.6	8
57	Mixup (Sample Pairing) Can Improve the Performance of Deep Segmentation Networks. <i>Journal of Artificial Intelligence and Soft Computing Research</i> , 2022, 12, 29-39.	4.3	8
58	Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Reviews in Oncology/Hematology, 2019, 134, 87-103.	4.4	7
59	Phase II prospective trial – Give Me Five – short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218). <i>Medical Oncology</i> , 2020, 37, 74.	2.5	7
60	Apparent Diffusion Coefficient and Other Preoperative Magnetic Resonance Imaging Features for the Prediction of Positive Surgical Margins in Prostate Cancer Patients Undergoing Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e335-e345.	1.9	7
61	High PD-L1 Expression on Tumor Cells Indicates Worse Overall Survival in Advanced Oral Squamous Cell Carcinomas of the Tongue and the Floor of the Mouth but Not in Other Oral Compartments. <i>Biomedicines</i> , 2021, 9, 1132.	3.2	7
62	Association of quantitative MRI-based radiomic features with prognostic factors and recurrence rate in oropharyngeal squamous cell carcinoma. <i>Neoplasma</i> , 2021, 67, 1437-1446.	1.6	7
63	Cone-beam CT-based inter-fraction localization errors for tumors in the pelvic region. <i>Physica Medica</i> , 2018, 46, 59-66.	0.7	6
64	A global Unified Dosimetry Index (gUDI) to evaluate simultaneous integrated boost radiotherapy plans in prostate cancer. <i>Radiotherapy and Oncology</i> , 2018, 128, 315-320.	0.6	6
65	Comparison of Outcomes and Toxicity Between Extreme and Moderate Radiation Therapy Hypofractionation in Localized Prostate Cancer: A Propensity Score Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 735-744.	0.8	6
66	Case series on multiple prostate re-irradiation for locally recurrent prostate cancer: something ventured, something gained. <i>Neoplasma</i> , 2019, 66, 308-314.	1.6	6
67	Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer. <i>Medical Oncology</i> , 2019, 36, 9.	2.5	6
68	Semi-Automated Segmentation of Bone Metastases from Whole-Body MRI: Reproducibility of Apparent Diffusion Coefficient Measurements. <i>Diagnostics</i> , 2021, 11, 499.	2.6	6
69	Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review. <i>Cancers</i> , 2021, 13, 3278.	3.7	6
70	High-Risk Prostate Cancer and Radiotherapy: The Past and the Future. A Benchmark for a New Mixed Beam Radiotherapy Approach. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 376-383.	1.9	5
71	Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome. <i>Ecancermedalscience</i> , 2017, 11, 786.	1.1	5
72	Back to (new) normality – A CODRAL/AIRO-L survey on cancer radiotherapy in Lombardy during Italian COVID-19 phase 2. <i>Medical Oncology</i> , 2020, 37, 108.	2.5	5

#	ARTICLE	IF	CITATIONS
73	COVID-19 safe and fully operational radiotherapy: An AIRO survey depicting the Italian landscape at the dawn of phase 2. <i>Radiotherapy and Oncology</i> , 2021, 155, 120-122.	0.6	5
74	Postoperative radiotherapy after upfront radical prostatectomy: debated issues at a turning point—a survey exploring management trends on behalf of AIRO (Italian Association of Radiotherapy and Oncology). <i>Radiotherapy and Oncology</i> , 2021, 155, 120-122.	1.0	6
75	COVID-19 impact in radiotherapy practice in an oncology hub: a screenshot from Lombardy, Italy. <i>Tumori</i> , 2021, 107, 030089162098006.	1.1	5
76	Feasibility of concurrent chemoradiotherapy with high-dose cisplatin after induction TPF chemotherapy in head and neck cancer: a critical review of the literature and the experience of the European Institute of Oncology. <i>Medical Oncology</i> , 2017, 34, 86.	2.5	4
77	Hadrontherapy from the Italian Radiation Oncologist point of view: face the reality. The Italian Society of Oncological Radiotherapy (AIRO) survey. <i>Radiologia Medica</i> , 2017, 122, 140-145.	7.7	4
78	Mixed-beam approach for high-risk prostate cancer: Carbon-ion boost followed by photon intensity-modulated radiotherapy. Dosimetric and geometric evaluations (AIRO IG-14300). <i>Physica Medica</i> , 2020, 76, 327-336.	0.7	4
79	Ultrahypofractionated radiotherapy for localized prostate cancer with simultaneous boost to the dominant intraprostatic lesion: a plan comparison. <i>Tumori</i> , 2022, 108, 263-269.	1.1	4
80	The T ₄ N ₁ tract involvement as a new prognostic factor for PORT in locally advanced oral cavity tumors. <i>Oral Diseases</i> , 2023, 29, 128-137.	3.0	4
81	Dosimetric Impact of Inter-Fraction Anatomical Changes in Carbon Ion Boost Treatment for High-Risk Prostate Cancer (AIRO IG 14300). <i>Frontiers in Oncology</i> , 2021, 11, 740661.	2.8	4
82	Repeat MRI during active surveillance: natural history of prostatic lesions and upgrading rates. <i>BJU International</i> , 2022, 129, 524-533.	2.5	4
83	Three weekly versus weekly concurrent cisplatin: safety propensity score analysis on 166 head and neck cancer patients. <i>Radiation Oncology</i> , 2021, 16, 239.	2.7	4
84	Finding safe dose-volume constraints for re-irradiation with SBRT of patients with prostate cancer relapse: The IEO experience. <i>Physica Medica</i> , 2021, 92, 62-68.	0.7	4
85	Palliative radiation therapy in bladder cancer: a matter of dose, techniques and patients' selection. <i>Annals of Palliative Medicine</i> , 2019, 8, 786-789.	1.2	3
86	Adjuvant radiotherapy in node positive prostate cancer patients: a debate still on. when, for whom?. <i>BJU International</i> , 2021, 127, 454-462.	2.5	3
87	COVID-19 and radiotherapy: impact on work and personal life of Lombardy residents during first lockdown, survey endorsed by AIRO Young. <i>Tumori</i> , 2021, , 030089162110008.	1.1	3
88	Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies. <i>World Journal of Urology</i> , 2021, , 1.	2.2	3
89	Oligometastatic Prostate Cancer: A Comparison between Multimodality Treatment vs. Androgen Deprivation Therapy Alone. <i>Cancers</i> , 2022, 14, 2313.	3.7	3
90	Workload of breast image-guided intensity-modulated radiotherapy delivered with TomoTherapy. <i>Tumori</i> , 2020, 106, 518-523.	1.1	2

#	ARTICLE	IF	CITATIONS
91	Almost one year of COVID-19 pandemic: how radiotherapy centers have counteracted its impact on cancer treatment in Lombardy, Italy. CODRAL/AIRO-L study. Tumori, 2022, 108, 177-181.	1.1	2
92	Re: Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. European Urology, 2021, 79, 889-890.	1.9	2
93	Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches. Frontiers in Oncology, 2021, 11, 732766.	2.8	2
94	Soft tissue necrosis in patients treated with transoral robotic surgery and postoperative radiotherapy: preliminary results. Tumori, 2020, 106, 471-479.	1.1	2
95	Recent Advances in the Management of Hormone-Sensitive Oligometastatic Prostate Cancer. Cancer Management and Research, 2022, Volume 14, 89-101.	1.9	2
96	EP-1338: High precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion. Radiotherapy and Oncology, 2017, 123, S717-S718.	0.6	1
97	Influence of different urinary bladder filling levels and controlling regions of interest selection on deformable image registration algorithms. Physica Medica, 2020, 75, 19-25.	0.7	1
98	Radiotherapy role in non-seminomatous germ cell tumors, radiobiological and technical issues of an unexplored scenario. International Journal of Clinical Oncology, 2021, 26, 1777-1783.	2.2	1
99	PH-0604 Hippocampal Sparing WBRT: Trade-Off Between Tumor Control And Quality Of Life? A series of 150 pts. Radiotherapy and Oncology, 2021, 161, S470-S471.	0.6	1
100	Biomedical omics: first insights of a new MSc degree of the University of Milan. Tumori, 2021, , 030089162110472.	1.1	1
101	Lung optimized treatment with CyberKnife® in inoperable lung cancer patients: feasibility analysis of a mono-institutional 115 patient series. Neoplasma, 2020, 67, 684-691.	1.6	1
102	Attitudes, practices and perspectives on imaging strategies in prostate cancer: a national cross-sectional survey involving expert radiation oncologists on behalf of AIRO (Italian association) Tj ETQq0 0 0 rgB15/Overlock 10 Tf 50	0.5	0
103	Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300. Frontiers in Oncology, 2021, 11, 778729.	2.8	1
104	PO-1254 SBRT vs 3D-CRT FOR OLIGOMETASTATIC BONE NSCLC. Radiotherapy and Oncology, 2022, 170, S1058-S1060.	0.6	1
105	EP-1085: EGFR expression in head and neck cancer : does it have a role as prognostic factor in radiotherapy?. Radiotherapy and Oncology, 2016, 119, S521-S522.	0.6	0
106	Combination of dabrafenib and radiotherapy: could skin toxicity be affected by different irradiation techniques?. BJR case Reports, 2016, 2, 20150493.	0.2	0
107	EP-1339: Feasibility and efficacy of moderately hypofractionated radiotherapy in high risk prostate cancer. Radiotherapy and Oncology, 2017, 123, S718.	0.6	0
108	EP-1342: Salvage stereotactic body radiotherapy for lymph node oligorecurrent prostate cancer. Radiotherapy and Oncology, 2017, 123, S719-S720.	0.6	0

#	ARTICLE	IF	CITATIONS
109	PO-0732: Toxicity and outcome in moderately hypofractionated radiotherapy for 590 prostate cancer patients. Radiotherapy and Oncology, 2017, 123, S384-S385.	0.6	0
110	PO-133: Occult lymphnode metastasis in early stage OPC treated with TORS without neck lymphnodes dissection. Radiotherapy and Oncology, 2017, 122, 64.	0.6	0
111	Physicists' Views on Hadrontherapy: A Survey of Members of the Italian Association of Medical Physics (AIFM). Tumori, 2017, 103, 430-437.	1.1	0
112	OC-0093: Give me five-Ultra Hypofractionated RT for localized Prostate Cancer: safety without losing efficacy. Radiotherapy and Oncology, 2018, 127, S49-S50.	0.6	0
113	PO-0699: Weight loss in head and neck cancer: proof of concept for a stepped-wedge nutritional protocol. Radiotherapy and Oncology, 2018, 127, S356-S357.	0.6	0
114	PO-1084: Short-term RT for early PCa with concomitant boost to the DIL : QoL after the end of the accrual. Radiotherapy and Oncology, 2018, 127, S610.	0.6	0
115	EP-1555: Multiple re-irradiation for locally recurrent prostate cancer: proof of concept and clinical outcome. Radiotherapy and Oncology, 2018, 127, S839.	0.6	0
116	EP-1565: Stereotactic Body Radiotherapy For Castration-Sensitive Prostate Cancer Bone Oligometastases. Radiotherapy and Oncology, 2018, 127, S843-S844.	0.6	0
117	EP-1625: Cyberknife Radiosurgery On Brain Metastases From Melanoma In The Era Of Systemic Target Therapy. Radiotherapy and Oncology, 2018, 127, S874-S875.	0.6	0
118	Ep-2372: High-Precision Salvage Re-Irradiation For Local Recurrence Of Prostate Cancer: Series Of 64 Patients. Radiotherapy and Oncology, 2018, 127, S1241-S1242.	0.6	0
119	PO-078 Radio-chemotherapy for Head and Neck cancer: retrospective comparison between weekly and three-weekly CDDP. Radiotherapy and Oncology, 2019, 132, 40.	0.6	0
120	PO-084 Quantification of the impact of radiologic imaging revision in Head and Neck cancer. Radiotherapy and Oncology, 2019, 132, 44.	0.6	0
121	PO-147 Functional outcome of postoperative IMRT after laryngeal conservative surgery. Radiotherapy and Oncology, 2019, 132, 77.	0.6	0
122	PO-182 Prognostic impact of hematological profile in oropharyngeal cancer treated with chemoradiotherapy. Radiotherapy and Oncology, 2019, 132, 95-96.	0.6	0
123	EP-1925 Association of MRI-based radiomic features with prognostic factors in oropharyngeal cancer. Radiotherapy and Oncology, 2019, 133, S1047-S1048.	0.6	0
124	PO-0854 Extreme vs moderate hypofractionation for localized Pca: a Propensity Score Matching Analysis. Radiotherapy and Oncology, 2019, 133, S449-S450.	0.6	0
125	EP-1139 Prognostic impact of hematological profile in oropharyngeal cancer treated with chemoradiotherapy. Radiotherapy and Oncology, 2019, 133, S632-S633.	0.6	0
126	EP-1156 Radical radio-chemotherapy in head and neck cancer: retrospective comparison between weekly and 3-weekly CDDP.. Radiotherapy and Oncology, 2019, 133, S641.	0.6	0

#	ARTICLE	IF	CITATIONS
127	EP-1160 Quantifying the impact of radiologic revision in head and neck cancer: monoinstitutional experience. <i>Radiotherapy and Oncology</i> , 2019, 133, S642-S643.	0.6	0
128	EP-1550 Give-me-five trial: toxicity assessment in ultra-hypofractionated prostate cancer radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 133, S836-S837.	0.6	0
129	EP-1921 Phase II AIRC-IG13218: Association of MRIbased radiomics with prognostic factors in prostate cancer. <i>Radiotherapy and Oncology</i> , 2019, 133, S1045.	0.6	0
130	EP-2066 Evaluation of ANACONDA performances varying the exploited subset of controlling ROIs (AIRC) Tj ETQq0 0,0 rgBT /Qoverlock 10	0.6	0
131	EP-1546 Stereotactic radiotherapy for prostate bed recurrence after prostatectomy, a multicentric series. <i>Radiotherapy and Oncology</i> , 2019, 133, S834-S835.	0.6	0
132	Assessment of awareness of human papillomavirus infection impact on oral cavity among patients. <i>Postepy Dermatologii I Alergologii</i> , 2021, 38, 985-993.	0.9	0
133	The role of palliative radiotherapy in the management of elderly and frail patients with advanced bladder cancer: A survey by the AIROÁuro-group. <i>Medical Oncology</i> , 2021, 38, 14.	2.5	0
134	Association between previous negative biopsies and lower rates of disease progression during active surveillance for prostate cancer. <i>European Urology</i> , 2021, 79, S1459.	1.9	0
135	PO-1794 Features robustness in the radiomic workflow: the impact of software choice on feature variability. <i>Radiotherapy and Oncology</i> , 2021, 161, S1519-S1520.	0.6	0
136	PO-1560 Evaluation of organ motion effect on dose in SBRT treatments for oligorecurrent prostate cancer. <i>Radiotherapy and Oncology</i> , 2021, 161, S1284-S1285.	0.6	0
137	PO-0995 Locally advanced nasopharyngeal carcinoma treated with a mixed beam (photons-protons) radiotherapy.. <i>Radiotherapy and Oncology</i> , 2021, 161, S827-S828.	0.6	0
138	PO-1796 Machine learning-based models of toxicity in prostate cancer ultra-hypofractionated radiotherapy. <i>Radiotherapy and Oncology</i> , 2021, 161, S1522-S1523.	0.6	0
139	PO-0961 Role of depth of infiltration (DOI) as independent prognostic factor in pT1–T2 N0 oral tongue SCC. <i>Radiotherapy and Oncology</i> , 2021, 161, S799-S800.	0.6	0
140	PD-0930 Comparison of automated segmentation techniques for magnetic resonance images of the prostate. <i>Radiotherapy and Oncology</i> , 2021, 161, S772-S773.	0.6	0
141	PO-1935 CLINICAL OUTCOMES AND RADIO-BIOLOGICAL FEATURES CORRELATION IN EARLY PCa: AN EXPLORATORY ANALYSIS. <i>Radiotherapy and Oncology</i> , 2021, 161, S1649-S1650.	0.6	0
142	PO-1355 Finding safe dose-volume constraints for re-irradiation of intraprostatic prostate cancer relapse.. <i>Radiotherapy and Oncology</i> , 2021, 161, S1112-S1113.	0.6	0
143	PO-1344 Preliminary results of Phase II trial on Carbon-ion boost followed by IMRT for high risk PCa. <i>Radiotherapy and Oncology</i> , 2021, 161, S1103-S1104.	0.6	0
144	PO-1359 PORT impact on biochemical recurrence in pN1 PCa patients: establishing the appropriate RT timing. <i>Radiotherapy and Oncology</i> , 2021, 161, S1115-S1116.	0.6	0

#	ARTICLE	IF	CITATIONS
145	SP-0038 SBRT. Radiotherapy and Oncology, 2021, 161, S12-S13.	0.6	0
146	Radiotherapy for the Treatment of Muscle-Invasive Bladder Cancer. , 2018, , 83-89.		0
147	Radiotherapy Plus Total Androgen Block Versus Radiotherapy Plus LHRH Analog Monotherapy for Non-metastatic Prostate Cancer. Anticancer Research, 2018, 38, 3139-3143.	1.1	0
148	MP67-08: SALVAGE ROBOT ASSISTED RADICAL PROSTATECTOMY VS SALVAGE RE-IRRADIATION FOR PATIENT WITH RADIO-RECURRENT PROSTATE CANCER AFTER PRIMARY RADIOTHERAPY: ONCOLOGICAL OUTCOMES. Journal of Urology, 2020, 203, .	0.4	0
149	The role of MRI in the management of a prostate cancer patient with bone and lymph nodes metastases. A case report. Acta Biomedica, 2021, 92, e2021214.	0.3	0
150	PO-1218: Oligo Metastatic renal cell carcinoma: SBRT, if, when and how?. Radiotherapy and Oncology, 2020, 152, S641-S642.	0.6	0
151	PO-1197: Short-term high precision RT for early PCa with SIB to the DIL: QoL assessment (AIRC IG 13218). Radiotherapy and Oncology, 2020, 152, S630-S631.	0.6	0
152	PO-1195: Impact of Adjuvant Radiotherapy in node positive prostate cancer patients. Radiotherapy and Oncology, 2020, 152, S629-S630.	0.6	0
153	OC-0694: An ESTRO-ACROP Delphi consensus on salvage SBRT for intraprostatic relapse after PCa radiotherapy. Radiotherapy and Oncology, 2020, 152, S387.	0.6	0
154	PO-1576: Assessment of mpMRI-based radiomics tools in PCa for cancer aggressiveness prediction, AIRC IG-. Radiotherapy and Oncology, 2020, 152, S854-S855.	0.6	0
155	PO-1023: Impact of biological features in radiosurgery for Brain metastases from Non Small Cell Lung Cancer. Radiotherapy and Oncology, 2020, 152, S545-S546.	0.6	0
156	PO-1748: Carbon-ion boost followed by photon IMRT for PCa: dosimetric and geometric evaluations, AIRCIG. Radiotherapy and Oncology, 2020, 152, S970-S971.	0.6	0
157	PO-0845: Role of postoperative RT (PORT) after compartmental surgery for locally advanced oral cavity tumors. Radiotherapy and Oncology, 2020, 152, S456.	0.6	0
158	PH-0118: Stereotactic or conventional RT for macroscopic prostate bed recurrence: a propensity score analysis. Radiotherapy and Oncology, 2020, 152, S59-S60.	0.6	0
159	Correlation between radiological and biological features and clinical outcomes in early prostate cancer: an exploratory subgroup analysis. Neoplasma, 2022, , .	1.6	0
160	Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer. World Journal of Urology, 2022, , 1.	2.2	0
161	Indication to post-operative radiotherapy for oral cavity squamous cell carcinoma: what's new in the depth of infiltration (DOI) era?. British Journal of Radiology, 2022, 95, 20210705.	2.2	0
162	Salvage stereotactic external beam re-irradiation for prostate cancer local failure: finding safe dose constraints for principal organs at risk. Physica Medica, 2021, 92, S197.	0.7	0

#	ARTICLE	IF	CITATIONS
163	Evaluation of effect on dose due to displacement of bowel and target volume in SBRT treatment for oligorecurrent crastation sensitive prostate cancer patients. <i>Physica Medica</i> , 2021, 92, S199.	0.7	0
164	Comparison of automated segmentation techniques for magnetic resonance images of the prostate. <i>Physica Medica</i> , 2021, 92, S52-S53.	0.7	0
165	PO-1546 Dosimetric characterization of PLA 3D printed boluses for external beam radiotherapy. <i>Radiotherapy and Oncology</i> , 2022, 170, S1327-S1329.	0.6	0
166	MO-0385 Added value of MRI radiomics to predict pathological status of prostate cancer patients. <i>Radiotherapy and Oncology</i> , 2022, 170, S320-S321.	0.6	0
167	MO-0551 Short-term RT for early PCa with concomitant boost to the DIL (phase II trial) Tj ETQq1 1 0.784314 rgBT /Oyerlock 10 Tf 50 58	0.6	0
168	PD-0412 Impact of adjuvant radiotherapy on biochemical recurrence rates for pn1 prostate cancer patients. <i>Radiotherapy and Oncology</i> , 2022, 170, S355-S356.	0.6	0
169	PO-1783 Leverage radiomic and clinical data in predicting SRS treatment outcomes in patients with brain mets. <i>Radiotherapy and Oncology</i> , 2022, 170, S1590-S1591.	0.6	0
170	PO-1360 Nutritional and inflammatory status as predictive biomarkers in oligorecurrent PCa (RADIOISA) Tj ETQq0 0.0 rgBT /Oyerlock 10	0.6	0
171	PO-1114 Intensity Modulated Radiotherapy (IMRT) after conservative surgery for supraglottic tumours. <i>Radiotherapy and Oncology</i> , 2022, 170, S947-S948.	0.6	0
172	PO-1772 Radiomic feature relevance in the prediction of pathological features of prostate cancer. <i>Radiotherapy and Oncology</i> , 2022, 170, S1576-S1578.	0.6	0
173	MO-0725 Hippocampal Sparing Wbrt: Trade-Off Between Tumor Control And Quality Of Life?. <i>Radiotherapy and Oncology</i> , 2022, 170, S635-S636.	0.6	0
174	PO-1190 Machine learning to predict locoregional relapse in pT1-2pN0-1 breast cancer following mastectomy. <i>Radiotherapy and Oncology</i> , 2022, 170, S1010-S1011.	0.6	0
175	PO-1765 Pre-processing and feature/volume correlation in CT radiomics in non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2022, 170, S1569-S1570.	0.6	0
176	PO-1482 Estimation of inter-fraction motion of pelvic organs in SBRT treatments of prostate oligometastases. <i>Radiotherapy and Oncology</i> , 2022, 170, S1257-S1258.	0.6	0